EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial

Alpana P Shukla iD, Julia P Dunn iD, Elisa Gomez Valderas, Julia Fraseur Brumm iD, Chrisanthi A Karanikas iD, Theresa Hunter Gibble iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70215 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Alpana P Shukla und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, Ne…. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Hypoglycemic Agents, Obesity, Overweight. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In SURMOUNT‐5, tirzepatide led to greater body weight (BW) reduction versus semaglutide in adults with obesity without T2D. Health‐related quality of life (HRQoL) with tirzepatide versus semaglutide in SURMOUNT‐5 was evaluated. Materials and Methods This analysis included on‐treatment data from participants who received ≥1 dose of tirzepatide or semaglutide at their maximum tolerated dose. Changes in prespecified Short Form‐36 Health Survey Version 2 (SF‐36v2) norm‐based scores for the Physical Component Summary (PCS), Mental Component Summary (MCS), and each domain, Patient Health Questionnaire‐9, and Patient Global Impression of Status for Physical Activity scores were assessed at Week 72. Post hoc analysis of changes in SF‐36v2 scores in participants with limited baseline physical function and by BW reduction thresholds was assessed at Week 72.

Results

Baseline scores were similar between treatments and among BW reduction categories. At Week 72, PCS scores improved from baseline with both treatments ( p < 0.001). However, MCS scores did not show significant improvements from baseline ( p > 0.05 for both treatment arms). All domain scores improved ( p ≤ 0.008), with greater improvements in General Health (GH) with tirzepatide versus semaglutide (5.45 vs. 4.20; p = 0.003). Participants with limited physical function improved in PCS, Physical Functioning (PF), and GH with tirzepatide versus semaglutide ( p ≤ 0.025). Higher BW reductions were associated with more improvement in PCS, PF, Role‐Physical, Bodily Pain (BP), GH, and Vitality scores with tirzepatide and semaglutide (pooled).

Conclusions

HRQoL improved with tirzepatide and semaglutide, with greater improvement in GH with tirzepatide, especially in participants with limited baseline physical function. Participants who lost the most BW showed the greatest improvements in PF, BP, and GH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesHypoglycemic AgentsObesityOverweightQuality of LifeTirzepatideAdultFemaleHumansMaleMiddle AgedTreatment OutcomeWeight LossGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

SF‐36v2SURMOUNT‐5health‐related quality of lifeobesitypatient‐reported outcomessemaglutidetirzepatide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsTirzepatideGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, New York, New York, USA.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Alpana P Shukla, Julia P Dunn, Julia Fraseur Brumm, Chrisanthi A Karanikas, Theresa Hunter Gibble

Förderung

  • Eli Lilly and Company

Zitieren

APA

Shukla, A. P., Dunn, J. P., Gomez Valderas, E., Fraseur Brumm, J., Karanikas, C. A., & Hunter Gibble, T. (2026). Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70215

Vancouver

Shukla AP, Dunn JP, Gomez Valderas E, Fraseur Brumm J, Karanikas CA, Hunter Gibble T. Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70215

BibTeX
@article{Shukla2026,
  author = {Shukla, Alpana P and Dunn, Julia P and Gomez Valderas, Elisa and Fraseur Brumm, Julia and Karanikas, Chrisanthi A and Hunter Gibble, Theresa},
  title = {Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70215}
}
Kostenlos starten →